Oxurion NV ( (GB:0G99) ) has issued an update.
Oxurion NV has announced changes to its Board of Directors, with the departure of Anat Loewenstein and Nathalie Laarakker, and the appointment of Nelly Souleymane as an independent director. This strategic move aims to enhance diversity and expertise within the board, bolstering Oxurion’s communication and reputation management efforts in the biopharmaceutical sector, and supporting the company’s development of innovative ophthalmic solutions.
More about Oxurion NV
Oxurion is a biopharmaceutical company based in Louvain, Belgium, focused on developing next-generation standard ophthalmic therapies for the treatment of retinal diseases.
Average Trading Volume: 3
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: €775K
For an in-depth examination of 0G99 stock, go to TipRanks’ Stock Analysis page.